Clinical Experience With 75-mg Dose of Erlotinib for Mutated Metastatic EGFR Non-small Cell Lung Cancer
Journal
American Journal of Therapeutics
ISSN
1075-2765
Date Issued
2019
Author(s)
Osvaldo Aren
Micahel Frelinghuysen
Mauricio Burotto
Type
Resource Types::text::journal::journal article
Subjects
lung cancer
;
target therapy
;
erlotinib
;
adult
;
aged
;
aged, 80 and over
;
antineoplastic combined chemotherapy protocols
;
carcinoma, non-small-cell lung
;
erbb receptors
;
erlotinib hydrochloride
;
female
;
humans
;
lung neoplasms
;
middle aged
;
mutation
;
protein kinase inhibitors
;
retrospective studies
;
treatment outcome
;
antineoplastic agent
;
egfr protein, human
;
epidermal growth factor receptor
;
erlotinib
;
protein kinase inhibitor
;
adult
;
aged
;
clinical trial
;
female
;
genetics
;
human
;
lung tumor
;
middle aged
;
mutation
;
non small cell lung cancer
;
phase 1 clinical trial
;
retrospective study
;
treatment outcome
;
very elderly